You are here

  • Home
  • Archive
  • Volume 4, Issue Suppl 1
  • 7 Utility of the lupus low disease activity state (LLDAS) definition in discriminating responders in the phase IIB muse trial of anifrolumab in systemic lupus erythematosus

Article metrics

Article menu

Download PDFPDF

Plenary Session 3: Challenges in drug development and clinical trial design in SLE
7 Utility of the lupus low disease activity state (LLDAS) definition in discriminating responders in the phase IIB muse trial of anifrolumab in systemic lupus erythematosus
Free

 

Online download statistics by month:

Online download statistics by month: March 2017 to March 2024

AbstractFullPdf
Mar 201714011
Apr 201723015
May 20171105
Jun 20171003
Jul 20172002
Aug 20171701
Sep 20172006
Oct 20171001
Nov 20171200
Dec 20172201
Jan 20184003
Feb 20182202
Mar 20181001
Apr 20181001
May 20181401
Jun 2018600
Jul 20181600
Aug 20182201
Sep 20181000
Oct 20181002
Nov 20181605
Dec 20181001
Jan 20191003
Feb 2019200
Mar 2019203
Apr 2019405
May 2019202
Jun 2019202
Jul 2019402
Aug 2019203
Sep 2019202
Oct 2019002
Nov 2019204
Dec 20191404
Jan 2020600
Feb 2020202
Mar 2020202
Apr 2020001
May 2020001
Jun 2020002
Jul 2020801
Aug 2020601
Sep 20202203
Oct 20202009
Nov 20201103
Dec 20201000
Jan 2021403
Feb 2021503
Mar 2021402
Apr 2021200
May 2021002
Jun 2021001
Jul 2021001
Aug 2021007
Sep 2021006
Oct 202120012
Nov 20214012
Dec 20211201
Jan 2022204
Feb 20221402
Mar 20221400
Apr 20221200
May 20222008
Jun 20221202
Jul 20222400
Aug 20221802
Sep 2022807
Oct 2022602
Nov 2022609
Dec 2022600
Jan 20231403
Feb 2023400
Mar 2023600
Apr 2023403
May 2023202
Jun 2023001
Jul 2023604
Aug 2023404
Sep 20232010
Oct 2023402
Nov 20232604
Dec 20232003
Jan 20241200
Feb 2024602
Mar 202412028
Total7930271